Influence of Helicobacter pylori Infection on Gut and Tumor Microbiomes and Its Relationship with Immunotherapy Outcomes in Gastrointestinal Malignancies - Report - MDSpire
Advertisement
Influence of Helicobacter pylori Infection on Gut and Tumor Microbiomes and Its Relationship with Immunotherapy Outcomes in Gastrointestinal Malignancies
Influence of Helicobacter pylori Infection on Gut and Tumor Microbiomes
Overview
Revise to specify the type of immunotherapy and clarify the relationship with H. pylori.
Background
Gastric cancer is a leading cause of cancer-related mortality globally, with H. pylori recognized as a significant carcinogen. The relationship between H. pylori infection and immunotherapy outcomes is emerging, suggesting that H. pylori may enhance the efficacy of immunotherapy in gastric cancer patients. Understanding the microbiome's role in this context is critical for optimizing treatment strategies.
Data Highlights
Group
Median irPFS (months)
p-value
H. pylori-positive
6.97
< 0.001
H. pylori-negative
5.03
Key Findings
H. pylori infection is associated with longer median immune-related progression-free survival (irPFS) in gastric cancer patients.
The study involved 218 gastric cancer patients, 134 esophageal squamous cell carcinoma patients, and 86 colorectal cancer patients.
H. pylori-positive patients showed significant differences in gut microbiome diversity compared to H. pylori-negative patients.
Functional enrichment analysis was performed to explore mechanisms underlying microbial changes related to immunotherapy response.
Intratumoral microbiome characteristics were associated with prognosis and therapeutic response in gastric cancer.
Clinical Implications
Clinicians should consider H. pylori infection status when evaluating immunotherapy options for gastric cancer patients, as it may influence treatment outcomes. Further research into the microbiome's role could lead to personalized therapeutic strategies that enhance immunotherapy efficacy.
Conclusion
The findings underscore the importance of H. pylori in shaping the microbiome and its potential role in improving immunotherapy outcomes in gastrointestinal malignancies. Continued exploration of these relationships is essential for advancing treatment approaches.
